# PAVmed Advances Veris Implantable Monitor Toward Early 2027 FDA Filing

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/56870
Published: 2026-11-13T16:10:11.000Z
Updated: 2026-11-13T16:10:11.000Z
Section: Business

> Veris Health’s monitor reached design freeze, and a 90-day GLP animal study began in October.

PAVmed Inc. is advancing Veris Health Inc.’s implantable physiological monitor toward an early 2027 submission to the U.S. Food and Drug Administration (FDA) through the 510(k) pathway. The device reached design freeze, and a 90-day GLP animal study began in October.

The FDA submission remains targeted for early 2027.